MANSFIELD – Medical technology maker Covidien PLC reported increased revenue but lower profit in the third quarter of its fiscal 2013, the company announced Thursday.
Covidien posted sales of $2.58 billion, a 2.9 percent increase from $2.51 billion in the fiscal 2012 third quarter.
At the same time, the company’s profit fell 12.6 percent to $396 million, or 84 cents per diluted share, from $453 million, or 93 cents per diluted share.
The drop in net income came in large part from the June spin-off of Covidien’s pharmaceuticals business, which is now held by Mallinckrodt PLC.
“In emerging markets, we again generated significant sales gains, reflecting the investments we’ve made to expand our sales force and build capabilities in these fast-growing regions,” Covidien Chairman, President and CEO José E. Almeida said in a statement. “With the pharmaceuticals spin-off now behind us, we are focused on strengthening our medical devices and supplies businesses through organic growth, new products and geographic expansion.”
Covidien’s medical device sales in the United States fell 4 percent in the third quarter to $910 million, from $952 million in the third quarter of 2012. Device sales grew 11 percent outside the U.S. to $1.2 billion in the quarter ended June 28.
Medical supplies sales fell in the U.S. as well, from $393 million to $389 million. Supplies sales held steady internationally, at $50 million.
Estate and Corporate Income Taxes are changing next year, and business owners and executives should know the details. The PBN Summit on November 6th will provide those details and more - including how much Obamacare's Employer Mandate could cost.
PBN's annual Book of Lists has been an essential resource for the local business community for almost 30 years. The Book of Lists features a wealth of company rankings from a variety of fields and industries, including banking, health care, real estate, law, hospitality, education, not-for-profits, technology and many more.